Supriya Lifescience has debuted at Rs 425.00 on the BSE, up by 151 points or 55.11% from its issue price of Rs 274.
The scrip is currently trading at Rs 396.90, up by 122.90 points or 44.85% from its issue price. It has touched a high and low of Rs 425.00 and Rs 388.20 respectively. So far 5.67 lakh shares were traded on the counter.
The offering, which was open for subscription between December 16, 2021 and December 20, 2021, was subscribed 71.51 times. The issue price was fixed at Rs 274 per share i.e. at upper end of price band of Rs 265-274 apiece.
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: